56 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Mar 21
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
9:01am
(setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency --
-- Announced positive … than 18 years old.
In November 2020, Rhythm announced that the U.S. Food and Drug Administration (FDA) approved IMCIVREE for chronic weight management
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
3 May 21
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
8:54am
was approved for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin (POMC … (PRV) for $100 million. The PRV was granted to Rhythm by the FDA with the approval of IMCIVREE for chronic weight management in adult and pediatric
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
(setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) for chronic … .
Setmelanotide Indication
In the United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
was approved by the FDA on June 16, 2022 for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to BBS … ) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
3 Feb 21
Regulation FD Disclosure
12:00am
Diseases * Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC , P CSK1 or LEPR … for chronic weight management in people with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor
8-K
EX-99.1
jc3sqp
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am
8-K
6qdqnhlqgnduqfdna1m
5 Jan 21
Entry into a Material Definitive Agreement
4:49pm
8-K
EX-99.1
duc27 9q2x3
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
u5kax71w zxcq2jhcv
3 Aug 21
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
1jkhx rbbwhm
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
8-K
EX-99.1
9euygm 84o8
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
ec7h1shfa ettkgi5
2 Nov 21
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
vbhcr3
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
EX-99.1
dsirihj zgddw0evkj
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
2an5a393
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am